Scientific Sessions 2024  /  GLP-1RAs and Beyond: Incretin Analogues and a New Frontier in Cardiovascular Therapeutics  /  Patient Interview
Logo

American Heart Association

  2
  0

Final ID:

Patient Interview

  • Ndumele, Chiadi  ( JOHNS HOPKINS HOSPITAL , Baltimore , Maryland , United States )
  • Taub, Pam  ( UCSD MEDICAL CENTER , La Jolla , California , United States )
    • Author Disclosures:
    Chiadi Ndumele: DO NOT have relevant financial relationships | Pam Taub: DO have relevant financial relationships ; Consultant:Amgen:Active (exists now) ; Consultant:Boehringer Ingelheim/Lilly:Active (exists now) ; Consultant:Sanofi:Active (exists now) ; Consultant:Medtronic:Active (exists now) ; Consultant:Edwards:Active (exists now) ; Consultant:Esperion:Active (exists now) ; Consultant:Novo Nordisk:Active (exists now) ; Consultant:Novartis:Active (exists now)
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

GLP-1RAs and Beyond: Incretin Analogues and a New Frontier in Cardiovascular Therapeutics

Sunday, 11/17/2024 , 09:45AM - 11:00AM

Main Event

More abstracts on this topic:
How are incretins PIONEERing metabolic care? Mechanisms of weight loss and risk factor reduction with incretin analogues

Nauck Michael, Drucker Daniel, Pratley Richard

Panel Discussion

Nauck Michael, Drucker Daniel, Pratley Richard

More abstracts from these authors:
Panelist - Prevention

Taub Pam

The Hidden Risk Factor: The Underappreciated Aspects of Lp(a) in ASCVD

Kaul Sanjay, Taub Pam

You have to be authorized to contact abstract author. Please, Login
Not Available